CNS & Neurological Disorders-Drug Targets
Scope & Guideline
Transforming Research into Therapeutic Solutions
Introduction
Aims and Scopes
- Pharmacological Research:
The journal emphasizes pharmacological studies on various compounds, including natural products, synthetic drugs, and biologics, aimed at understanding their mechanisms of action in treating neurological disorders. - Neurodegenerative Disorders:
A significant focus is placed on neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS), exploring novel therapeutic targets and treatment paradigms. - Neuroinflammation and Neuroprotection:
Research related to neuroinflammation and neuroprotective strategies is a core area, addressing the role of immune responses and potential therapeutic interventions to mitigate neuroinflammatory damage. - Neuropsychiatric Disorders:
The journal also covers neuropsychiatric conditions, investigating the interplay between neurological and psychiatric symptoms, treatment efficacy, and new pharmacological approaches. - Innovative Drug Delivery Systems:
There is a keen interest in exploring novel drug delivery systems, including nanotechnology and transdermal systems, to enhance the efficacy of treatments for CNS disorders. - Molecular Mechanisms and Biomarkers:
The journal promotes research on molecular mechanisms underlying neurological disorders, including the identification of biomarkers for early diagnosis and monitoring of therapeutic responses.
Trending and Emerging
- Microbiome-Gut-Brain Axis:
Recent studies have highlighted the significance of the microbiome-gut-brain axis in neurological disorders, indicating a growing interest in how gut health influences brain function and disease progression. - Neuroinflammation as a Therapeutic Target:
There is an increasing focus on neuroinflammation and its role in various neurological conditions, with research exploring anti-inflammatory strategies as potential therapeutic approaches. - Nanotechnology in Drug Delivery:
Emerging research on nanotechnology for drug delivery systems is gaining momentum, showcasing innovative methods to enhance the bioavailability and efficacy of treatments for CNS disorders. - Genetic and Epigenetic Research:
Investigations into genetic and epigenetic factors influencing neurological disorders are on the rise, emphasizing personalized medicine and targeted therapeutic interventions. - Artificial Intelligence and Machine Learning:
The integration of artificial intelligence and machine learning in analyzing neurological data is becoming a prominent theme, aiding in diagnosis, treatment planning, and outcome prediction. - Phytochemicals and Natural Products:
There is a renewed interest in the therapeutic potential of phytochemicals and natural products, with research focusing on their mechanisms of action and efficacy in neurological conditions.
Declining or Waning
- Traditional Herbal Medicine:
The interest in traditional herbal remedies as standalone treatments has diminished, possibly due to an increasing focus on evidence-based pharmacological approaches and the need for standardized treatment protocols. - Basic Animal Models:
The reliance on basic animal models for studying neurological diseases appears to be waning, as there is a growing emphasis on more sophisticated models that better replicate human conditions and disease mechanisms. - Single Agent Studies:
Research focusing solely on the efficacy of single-agent therapies is declining, with a shift towards combination therapies that address the multifactorial nature of neurological disorders. - Epidemiological Studies:
There seems to be a reduction in the publication of purely epidemiological studies, as the journal increasingly prioritizes studies that integrate clinical findings with molecular and pharmacological research.
Similar Journals
BIOCHEMICAL PHARMACOLOGY
Advancing drug discovery through biochemical insights.BIOCHEMICAL PHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, stands as a leading international journal devoted to the advancing field of biochemical pharmacology. Since its inception in 1958, the journal has continuously offered a platform for innovative research, delivering critical insights into the interaction between biochemical processes and pharmaceutical applications, and now converges towards its 2024 edition. With an impressive Q1 ranking in both Biochemistry and Pharmacology categories, it ranks 32nd out of 313 in Pharmacology and Toxicology, and 58th out of 438 in Biochemistry according to Scopus, showcasing its significant impact within the scientific community. Researchers and professionals rely on this journal to keep abreast of essential developments, given its robust peer-review process and a comprehensive selection of articles that span experimental studies, clinical trials, and theoretical analyses. Although not an Open Access journal, it remains pivotal for those seeking to advance their knowledge in the dynamic fields of biochemistry and pharmacology. With its high impact factor and emphasis on quality research, BIOCHEMICAL PHARMACOLOGY continues to be an invaluable resource for students, researchers, and industry professionals striving to make breakthroughs in drug development and therapeutic strategies.
Current Molecular Pharmacology
Advancing the Frontiers of PharmacologyCurrent Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.
ACS Chemical Neuroscience
Illuminating the Chemical Foundations of Brain Activity.ACS Chemical Neuroscience, published by the American Chemical Society, is a premier journal dedicated to exploring the complex interactions between chemistry and neuroscience. With its ISSN 1948-7193 and a distinguished impact factor that positions it within the top quartiles across multiple categories, including Q1 in Biochemistry, Q2 in Cell Biology, and Q1 in Physiology, this journal serves as an essential platform for researchers engaged in cutting-edge studies from 2010 to 2024. Positioned within the top 15% of its field in Cognitive Neuroscience according to Scopus rankings, ACS Chemical Neuroscience strives to foster interdisciplinary collaboration, publishing significant advancements that integrate chemical concepts with neurological processes. Despite its traditional publication model, the journal is committed to maintaining rigorous peer-review standards and providing valuable insights that drive innovations in therapeutics and understanding the biochemical underpinnings of brain function. Researchers, professionals, and students alike will find in this journal a vital resource for the latest findings and methodologies in the dynamic intersection of chemistry and neuroscience.
CNS DRUGS
Advancing Neuroscience through Innovative PharmacotherapyCNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.
NEUROMOLECULAR MEDICINE
Advancing the Frontiers of Neuroscience and Molecular MedicineNEUROMOLECULAR MEDICINE, published by HUMANA PRESS INC, is a prestigious peer-reviewed journal dedicated to advancing the fields of cellular and molecular neuroscience, molecular medicine, and neurology. With an ISSN of 1535-1084 and an E-ISSN of 1559-1174, the journal boasts a significant presence in academic research since its inception in 2002 and continues to publish cutting-edge studies through 2024. Ranked in the Q2 category for 2023 in various disciplines, including Neuroscience and Molecular Medicine, it holds impressive positions in Scopus rankings, including 41st out of 192 in Neuroscience and Neurology. Although not an open access journal, NEUROMOLECULAR MEDICINE remains invaluable for researchers, professionals, and students seeking to explore the intricate relationships between molecular mechanisms and neurological functions, thereby contributing to the scientific understanding of nervous system diseases and therapeutic innovations.
International Journal of Molecular and Cellular Medicine
Exploring Innovations in Cell Biology and GeneticsInternational Journal of Molecular and Cellular Medicine, published by the CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTER in Iran, is a leading platform dedicated to advancing research in various domains of molecular and cellular sciences. With an ISSN of 2251-9637 and E-ISSN 2251-9645, this journal features a rigorous peer-review process that ensures the publication of high-quality, impactful research. Spanning from 2016 to 2024, it is categorized in the third quartile (Q3) in Biochemistry, Cell Biology, Genetics, and Molecular Biology, and second quartile (Q2) in Biotechnology, underlining its significance in the scientific community. Although currently non-open access, it maintains credible visibility through Scopus rankings, reflecting its importance in fields such as Biochemistry, Molecular Medicine, and Genetics, where it holds respectable ranks and percentiles. This journal aims to foster collaboration and knowledge dissemination among researchers, professionals, and students in the pursuit of enhancing understanding and innovation in molecular and cellular medicine.
MOLECULAR THERAPY
Connecting researchers to reshape the future of medicine.MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
Unveiling the Secrets of Life through Cutting-edge Science.ACTA BIOCHIMICA ET BIOPHYSICA SINICA, an esteemed journal published by SCIENCE PRESS, is a leading platform in the fields of biochemistry, biophysics, and molecular biology. Based in the United Kingdom, this journal has consistently ranked in the Q2 category for Biochemistry, Biophysics, and Medicine (miscellaneous) in 2023, showcasing its commitment to high-quality research and innovation in life sciences. With a convergence period extending from 1996 to 2024, it features critical insights into biochemical and biophysical processes that underlie biological phenomena. Researchers and professionals seeking to stay at the forefront of discoveries will find its articles to be both informative and transformative. Although not an open-access journal, ACTA BIOCHIMICA ET BIOPHYSICA SINICA aims to advance knowledge and foster collaboration among scientists worldwide, emphasizing its role in the dynamic landscape of biomedical research.
DRUG DEVELOPMENT RESEARCH
Exploring the frontiers of drug discovery and development.DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.
Letters in Drug Design & Discovery
Unveiling Novel Approaches in Drug Design & DiscoveryLetters in Drug Design & Discovery is an esteemed journal dedicated to advancing the fields of Drug Discovery and Molecular Medicine. Published by Bentham Science Publishers, this journal offers a platform for the dissemination of innovative research and advanced methodologies, enhancing collaboration among researchers and professionals in pharmaceutical sciences. Despite its current Q4 ranking in Drug Discovery and Molecular Medicine and Q3 in Pharmaceutical Science for 2023, the journal is committed to improving its presence in the academic community by providing quality, peer-reviewed publications that cover various aspects of drug design and discovery, including novel therapeutic approaches and methodologies. With a focus on both foundational and cutting-edge research from around the globe, Letters in Drug Design & Discovery is pivotal for those seeking to stay abreast of developments in drug development and molecular research. Researchers are encouraged to submit their work, engage with the burgeoning field, and contribute to the ongoing dialogue driven by this journal, which spans the years from 2005 to 2024. While the journal does not currently offer open access, its contributions remain accessible to a wide range of academic and professional audiences.